AstraZeneca (AZ) has unveiled early data for its next-generation PARP1 selective inhibitor AZD5305 – a potential successor to its blockbuster PARP treatment Lynparza.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,